



Tokyo, November 25, 2019

FOR IMMEDIATE RELEASE

Transfer of rights to uricosuric agent URINORM®

Today, Torii Pharmaceutical Co., Ltd (Torii) (TSE:4551) has announced that TOA EIYO LTD. (TOA EIYO) will acquire the marketing authorization and take over the marketing activities for uricosuric agent URINORM® Tablet 50mg and 25mg from Torii on April 1, 2020.

1. Rationale of the transfer

URINORM has long been used for treatments of gout and hyperuricemia for many patients as one of main products of Torii since 1979. Torii intends to focus on extending and maximizing values of the new products and transfer URINORM, based on the drastic reform of the drug price system.

2. Overview of the transfer

| | |
|------------|---|
| Products | URINORM® Tablet 50mg URINORM® Tablet 25mg |
| Indication | Gout |
| | Hypertension accompanied by hyperuricemia |
| Launch | URINORM® Tablet 50mg : April, 1979 URINORM® Tablet 25mg : June, 1984 |
| Sales | 600 million yen in 2018 |

TOA EIYO will be responsible for not only providing and gathering URINORM's information but also supplying URINORM stably from April 1, 2020. Torii will continue to be responsible for distribution.

Torii will receive a consideration from TOA EIYO. TOA EIYO and Torii don't disclose the amount of consideration because of business circumstances.

3. Overview of TOA EIYO

| | |
|--------------------|---|
| (1) Name | TOA EIYO LTD. |
| (2) Address | 10-6,Hatchobori 3-chome,Chuo-ku,Tokyo,Japan |
| (3) Representative | President : Atsuo Takahashi |
| (4) Business | Manufacture and Sale of Pharmaceuticals |
| (5) Capital | 300million yen |

| | | |
|-----------------------------|--|------|
| (6) Foundation | October,1943 | |
| (7) Total Equity | 54,555 million yen (As of March 31,2019) | |
| (8) Total Assets | 65,015 million yen (As of March 31,2019) | |
| (9) Relationship with Torii | Capital | None |
| | Personnel | None |
| | Business | None |
| | Related party | None |

4. Schedule

| | |
|---------------------------|-------------------|
| (1)The date of Decision | November 25, 2019 |
| (2)The date of agreements | November 25, 2019 |
| (3)The date of transfer | April 1, 2020 |

5. Impact on Financial Performance

The effects of this transfer on the business performance of Torii's in this fiscal year will be immaterial. The effects on the business performance for the fiscal year ending December 2020, are to be included in Torii's forecasts to be announced on February 6, 2020.

Contact for Torii Pharmaceutical Co., Ltd.:
Corporate Planning Department
(Public Relations)
Torii Pharmaceutical Co., Ltd.
Tokyo: +81-3-3231-6814